Literature DB >> 14638398

Short duration aerosols of JNJ 2408068 (R170591) administered prophylactically or therapeutically protect cotton rats from experimental respiratory syncytial virus infection.

Philip R Wyde1, Srikrishna N Chetty, Philip Timmerman, Brian E Gilbert, Koen Andries.   

Abstract

Cotton rats exposed to continuous small droplet aerosols of 2[[2-[[1-(2-aminoethyl)-4-piperidinyl]amino]-4-methyl-1H-benzimidazol-1-yl]methyl]-6-methyl-3-pyridinol (JNJ 2408068) or its hydrochloric salt for only 15 min, one day prior to virus inoculation or one day after, were significantly protected from pulmonary respiratory syncytial virus (RSV) infection compared to control animals similarly infected but exposed to aerosols of placebo at these times. No evidence of toxicity was seen in any of these animals or in cotton rats administered 10 times the minimum cotton rat efficacious dose (i.e. 10x0.39 mg of active compound per kilogram of body weight) for four continuous days. The marked selective antiviral activity observed in the cotton rats mirrored that seen for these compounds in cytotoxicity and antiviral assays performed against RSV in vitro. Plasma kinetics and tissue distribution of JNJ 2408068 in cotton rats following inhalation were determined in separate experiments performed using conditions similar to those utilized in the in vivo efficacy studies. The data from these experiments indicated that significant levels of the test compound were delivered to the lungs of exposed animals, but that extrapulmonary distribution was limited.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14638398     DOI: 10.1016/j.antiviral.2003.07.002

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  15 in total

1.  Mathematical modelling identifies the role of adaptive immunity as a key controller of respiratory syncytial virus in cotton rats.

Authors:  Darren Wethington; Olivia Harder; Karthik Uppulury; William C L Stewart; Phylip Chen; Tiffany King; Susan D Reynolds; Alan S Perelson; Mark E Peeples; Stefan Niewiesk; Jayajit Das
Journal:  J R Soc Interface       Date:  2019-11-27       Impact factor: 4.118

2.  Blocking Respiratory Syncytial Virus Entry: A Story with Twists.

Authors:  Marco Weisshaar; Robert Cox; Richard K Plemper
Journal:  DNA Cell Biol       Date:  2015-05-11       Impact factor: 3.311

Review 3.  Targeting RSV with vaccines and small molecule drugs.

Authors:  Heather M Costello; William C Ray; Supranee Chaiwatpongsakorn; Mark E Peeples
Journal:  Infect Disord Drug Targets       Date:  2012-04

4.  Small molecules VP-14637 and JNJ-2408068 inhibit respiratory syncytial virus fusion by similar mechanisms.

Authors:  Janet L Douglas; Marites L Panis; Edmund Ho; Kuei-Ying Lin; Steve H Krawczyk; Deborah M Grant; Ruby Cai; Swami Swaminathan; Xiaowu Chen; Tomas Cihlar
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

5.  Use of a highly sensitive strand-specific quantitative PCR to identify abortive replication in the mouse model of respiratory syncytial virus disease.

Authors:  Richard Bannister; Deborah Rodrigues; Edward J Murray; Carl Laxton; Mike Westby; Helen Bright
Journal:  Virol J       Date:  2010-09-22       Impact factor: 4.099

6.  (S)-N-(2,5-Dimethylphenyl)-1-(quinoline-8-ylsulfonyl)pyrrolidine-2-carboxamide as a small molecule inhibitor probe for the study of respiratory syncytial virus infection.

Authors:  Blake P Moore; Dong Hoon Chung; Daljit S Matharu; Jennifer E Golden; Clinton Maddox; Lynn Rasmussen; James W Noah; Melinda I Sosa; Subramaniam Ananthan; Nichole A Tower; E Lucile White; Fuli Jia; Thomas E Prisinzano; Jeffrey Aubé; Colleen B Jonsson; William E Severson
Journal:  J Med Chem       Date:  2012-10-16       Impact factor: 7.446

7.  Oral efficacy of a respiratory syncytial virus inhibitor in rodent models of infection.

Authors:  Christopher Cianci; Eugene V Genovesi; Lucinda Lamb; Ivette Medina; Zheng Yang; Lisa Zadjura; Hyekyung Yang; Celia D'Arienzo; Ny Sin; Kuo-Long Yu; Keith Combrink; Zhufang Li; Richard Colonno; Nicholas Meanwell; Junius Clark; Mark Krystal
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

8.  Structure-guided design of small-molecule therapeutics against RSV disease.

Authors:  Robert Cox; Richard K Plemper
Journal:  Expert Opin Drug Discov       Date:  2016-04-21       Impact factor: 6.098

9.  Antibacterial, Antitubercular and Antiviral Activity Evaluations of Some Arylidenehydrazide Derivatives Bearing Imidazo[2,1-b]thiazole Moiety.

Authors:  Nuray Ulusoy Güzeldemirci; Berin Karaman; Ömer Küçükbasmaci
Journal:  Turk J Pharm Sci       Date:  2017-08-15

Review 10.  Emerging drugs for respiratory syncytial virus infection.

Authors:  Wieslawa Olszewska; Peter Openshaw
Journal:  Expert Opin Emerg Drugs       Date:  2009-06       Impact factor: 4.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.